#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2640	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2118	359.4	0	.	n	.	0	A662G	SNP	662	662	A	924	924	G	371	G	320	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2640	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2118	359.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1712	1712	T	399	T	357	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2640	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2118	359.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1446	1446	C	425	C	368	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4542	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3861	352.9	0	.	n	.	0	G262A	SNP	262	262	G	726	726	A	452	A	401	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4542	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3861	352.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1801	1801	A	355	A	313	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4542	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3861	352.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2435	2435	C	425	C,T	366,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4542	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3861	352.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2509	2509	A	442	A,G	381,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4542	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3861	352.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3061	3061	C	431	C,A	366,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	368	folP	852	852	99.77	folP.l15.c4.ctg.1	1869	59.2	0	.	p	.	0	S68P	NONSYN	202	204	TCG	694	696	CCG	93;93;93	C;C;G	77;77;76	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	368	folP	852	852	99.77	folP.l15.c4.ctg.1	1869	59.2	0	.	p	.	0	A204V	NONSYN	610	612	GCA	1102	1104	GTA	80;80;79	G;T;A	70;66;68	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	368	folP	852	852	99.77	folP.l15.c4.ctg.1	1869	59.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1174	1176	AGC	89;89;89	A;G;C	74;75;72	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	740	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3758	59.1	1	SNP	p	S91F	0	.	.	271	273	TCC	740	742	TCC	61;61;62	T;C;C	56;57;58	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	740	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3758	59.1	1	SNP	p	D95G	0	.	.	283	285	GAC	752	754	GAC	61;61;62	G;A;C,T	56;55;54,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	740	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3758	59.1	1	SNP	p	D95N	0	.	.	283	285	GAC	752	754	GAC	61;61;62	G;A;C,T	56;55;54,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	27	278	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1600	52.0	1	SNP	p	G45D	0	.	.	133	135	GGC	609	611	GGC	74;74;73	G;G;C	65;65;65	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	216	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1309	49.5	0	.	n	.	0	.206T	INS	206	206	T	759	759	T	78	T	69	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	728	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3313	65.8	0	.	p	.	0	G459S	NONSYN	1375	1377	GGT	1886	1888	AGT	104;102;101	A,G;G;T	89,1;86;86	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	728	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3313	65.8	1	SNP	p	D86N	0	.	.	256	258	GAC	767	769	GAC	75;75;74	G;A;C	65;64;64	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	728	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3313	65.8	1	SNP	p	S87I	0	.	.	259	261	AGT	770	772	AGT	74;74;74	A;G,T;T	60;62,1;62	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	728	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3313	65.8	1	SNP	p	S87R	0	.	.	259	261	AGT	770	772	AGT	74;74;74	A;G,T;T	60;62,1;62	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	728	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3313	65.8	1	SNP	p	S87W	0	.	.	259	261	AGT	770	772	AGT	74;74;74	A;G,T;T	60;62,1;62	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	728	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3313	65.8	1	SNP	p	S88P	0	.	.	262	264	TCC	773	775	TCC	74;74;75	T;C;C	63;65;63	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	682	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3009	67.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1733	1735	GGC	89;89;89	G;G;C	78;80;79	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1418	1420	GCA	99;99;99	G;C;A	85;85;86	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1421	1423	ATC	99;99;99	A;T,C;C	84;85,1;85	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1433	1435	GTG	99;99;99	G,T;T;G	86,1;88;88	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1433	1435	GTG	99;99;99	G,T;T;G	86,1;88;88	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1937	1939	ACC	94;94;94	A;C;C	82;81;82	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1991	1993	GCG	87;87;87	G;C;G	78;73;73	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1991	1993	GCG	87;87;87	G;C;G	78;73;73	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2114	2116	GGT	87;87;87	G;G;T	72;73;71	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2123	2125	GGC	88;88;88	G;G;C	74;74;74	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	668	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2703	73.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2141	2143	CCG	91;92;92	C;C;G	73;76;74	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	976	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3331	87.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	320	porA	1146	1146	99.48	porA.l15.c4.ctg.1	2132	44.9	0	.	p	.	0	S22G	NONSYN	64	66	AGC	537	539	GGC	51;51;52	G;G;C	46;46;45	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	320	porA	1146	1146	99.48	porA.l15.c4.ctg.1	2132	44.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	719	719	C	48	C	43	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	512	porB1b	1041	1041	96.95	porB1b.l15.c30.ctg.1	1611	92.5	0	.	p	.	0	T18M	NONSYN	52	54	ACG	361	363	ATG	121;121;121	A;T;G	100;99;99	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	512	porB1b	1041	1041	96.95	porB1b.l15.c30.ctg.1	1611	92.5	0	.	p	.	0	T26A	NONSYN	76	78	ACC	385	387	GCC	124;123;123	G;C;C	98;99;101	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	512	porB1b	1041	1041	96.95	porB1b.l15.c30.ctg.1	1611	92.5	0	.	p	.	0	K41D	NONSYN	121	123	AAA	430	432	GAC	130;130;130	G;A;C	109;109;111	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	512	porB1b	1041	1041	96.95	porB1b.l15.c30.ctg.1	1611	92.5	0	.	p	.	0	G140R	NONSYN	418	420	GGA	727	729	AGA	102;103;103	A;G;A	91;91;89	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	512	porB1b	1041	1041	96.95	porB1b.l15.c30.ctg.1	1611	92.5	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	736	738	CAA	101;101;103	C;A;A	89;89;92	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	512	porB1b	1041	1041	96.95	porB1b.l15.c30.ctg.1	1611	92.5	0	.	p	.	0	I209M	NONSYN	625	627	ATC	934	936	ATG	94;94;97	A;T;G	82;81;84	.	.
porB1b.WHO_O_01976	porB1b.WHO_O_01976	1	1	539	512	porB1b	1041	1041	96.95	porB1b.l15.c30.ctg.1	1611	92.5	0	.	p	.	0	Y212fs	FSHIFT	634	634	T	943	943	T	95	T	80	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1926	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	5178	111.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2177	2179	CAT	133;133;133	C;A;T	116;113;114	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	298	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1301	68.5	1	SNP	p	V57M	1	.	.	169	171	ATG	671	673	ATG	126;126;126	A;T;G	103;102;102	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
